Poseida Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company. The Company provides differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing.

Employees

350

Sector

Biotechnology & Medical Research

More about the company

Delayed Nasdaq 00:00:00 08/01/2025 +03			5-day change	1st Jan Change
9.500 ^USD	-0.63%		-.--%	-

10/01/25	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from S&P TMI Index	CI
09/01/25	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Composite Index	CI

Market Cap	939M 824M 774M 708M 1.32B 89.91B 1.33B 9.3B 3.61B 45.84B 3.52B 3.45B 149B	P/E 2022	-5.96x	P/E 2023	-2.45x
Enterprise Value	812M 713M 670M 612M 1.14B 77.77B 1.15B 8.05B 3.12B 39.65B 3.05B 2.98B 129B	EV / Sales 2022	2,006,182x	EV / Sales 2023	3,006,338x
Free-Float	72.36%	Yield 2022 *	-	Yield 2023	-

10/01/25	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from S&P TMI Index	CI
09/01/25	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Composite Index	CI
09/01/25	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from S&P Global BMI Index	CI
08/01/25	Swiss Market Index Extends Winning Streak; Partners Group Gains	MT
08/01/25	Poseida Therapeutics Acquisition Set to Be Completed, Roche Says	MT
08/01/25	Roche: Poseida acquisition nears completion
08/01/25	Roche to Complete Takeover of Poseida Therapeutics After Tender Offer Closes	MT
08/01/25	Roche to complete acquisition of U.S. biopharma company Poseida	RE
07/01/25	Roche Holdings, Inc. completed the acquisition of Poseida Therapeutics, Inc. from Malin Corporation PLC, Pentwater Capital Management and others.	CI
12/12/24	Poseida Therapeutics Insider Sold Shares Worth $283,866, According to a Recent SEC Filing	MT
10/12/24	Roche: launch of takeover bid for Poseida Therapeutics
10/12/24	Roche Launches Tender Offer for Poseida Therapeutics	MT
09/12/24	Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform	MT

02/12/24	Piper Sandler Downgrades Poseida Therapeutics to Neutral, $10 Price Target	MT
26/11/24	Cantor Fitzgerald Downgrades Poseida Therapeutics to Neutral From Overweight	MT
26/11/24	BTIG Downgrades Poseida Therapeutics to Neutral	MT
11/12/23	Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating	MT
11/12/23	HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating	MT

Poseida Therapeutics, Inc. Stock

Stocks

PSTX

US73730P1084

Biotechnology & Medical Research

Valuation: Poseida Therapeutics, Inc.

Latest news: Poseida Therapeutics, Inc.

Analysts' recommendations: Poseida Therapeutics, Inc.

Press Releases: Poseida Therapeutics, Inc.

News in other languages: Poseida Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Poseida Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

28/11/24	POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX	BU
27/11/24	Poseida Therapeutics, Inc. Announces Agreement to be acquired by Roche Holdings, Inc.	AQ
26/11/24	Poseida Therapeutics : Announces Agreement to be Acquired by Roche Holdings, Inc Form 8 K	PU
14/11/24	Poseida Therapeutics : Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline Form 8 K	PU
14/11/24	Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline	PR

08/01/25	Roche : l'acquisition de Poseida en passe d'être finalisée
08/01/25	Roche reprend la majorité de Poseida Therapeutics
08/01/25	Roche steht kurz vor Abschluss der Poseida-Übernahme
10/12/24	En Direct des Marchés : Vivendi fait des petits, Euroapi change tout, Oracle voit trouble
10/12/24	Wall Street vacille, l'Europe s'éparpille, la Chine scintille

Manager	Title	Age	Since
Dara Pincas CEO	Chief Executive Officer	-	-
Johanna Mylet DFI	Director of Finance/CFO	39	01/07/2020
Syed Rizvi CTO	Chief Tech/Sci/R&D Officer	59	01/04/2024

Director	Title	Age	Since
Sean Johnston BRD	Director/Board Member	-	08/01/2025
Roger Brown BRD	Director/Board Member	-	08/01/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/8/25 A	Charles Baum	Tender	Director	190,300	0.1952%
1/8/25 A	Rafael Amado	Tender	Director	141,500	0.1452%
1/8/25 A	MALIN CORP. PLC	Tender	Company	11,835,673	12.1435%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POSEIDA THERAPEUTICS, INC.	-0.63%	-.--%	-.--%	+400.00%	929M
WUXI APPTEC CO., LTD.	+0.06%	+7.20%	+54.04%	+111.13%	74.27B
ARGENX SE	-2.29%	-1.51%	+33.30%	+75.15%	61.21B
WUXI BIOLOGICS (CAYMAN) INC.	+0.28%	+7.27%	+31.74%	+23.80%	27.55B
INSMED INCORPORATED	-1.95%	-3.37%	-18.52%	+359.46%	26.38B
BIONTECH SE	-1.96%	+3.26%	+0.69%	-4.04%	25.34B
GENMAB A/S	+0.57%	+3.66%	+25.59%	-9.08%	20.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.47%	+4.46%	-8.09%	+513.33%	14.94B
PHARMAESSENTIA CORPORATION	+1.29%	-2.49%	+163.31%	+333.06%	15.17B
EXELIXIS, INC.	-2.44%	-0.35%	+42.12%	+159.18%	14.41B
Average	-0.84%	+2.88%	+32.42%	+196.20%	28.1B
Weighted average by Cap.	-0.90%	+3.07%	+35.41%	+135.53%

	2022	2023
Net sales	130.49 114.53 107.66 98.43 183.93 12.5K 185.3 1.29K 501.32 6.37K 490.04 479.3 20.66K	64.7 56.79 53.38 48.81 91.2 6.2K 91.88 641.2 248.58 3.16K 242.98 237.65 10.25K
Net income	-64M -56.17M -52.8M -48.28M -90.21M -6.13B -90.88M -634M -246M -3.13B -240M -235M -10.13B	-123M -108M -102M -93.1M -174M -11.82B -175M -1.22B -474M -6.03B -464M -453M -19.54B
Net Debt	-194M -170M -160M -146M -273M -18.56B -275M -1.92B -744M -9.46B -728M -712M -30.68B	-127M -111M -105M -95.63M -179M -12.14B -180M -1.26B -487M -6.19B -476M -466M -20.07B

3 years	1.83	9.67
5 years	1.54	9.67
10 years	1.54	17.62